Beyondspring Stock

Beyondspring Current Liabilities

The Current Liabilities of Beyondspring (BYSI) as of Sep 4, 2026 is 11.01 M USD. In the previous year, Current Liabilities was 7.96 M USD — a change of 38.35% (higher).

Current Liabilities

11.01 MUSD

YoY

38.35%

Last updated:

Current Liabilities of Beyondspring is 2026 11.01 M USD. Current Liabilities of Beyondspring was 2025 7.96 M USD. It decreases by 38.35% higher compared to the previous year.

The Beyondspring Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2017
4.79 M USD
Jan 1, 2018
16.45 M USD
Jan 1, 2019
10.05 M USD
Jan 1, 2020
13.77 M USD
Jan 1, 2021
15.16 M USD
Jan 1, 2022
7.35 M USD
Jan 1, 2023
7.96 M USD
Jan 1, 2024
11.01 M USD
The Beyondspring Current Liabilities history
YEARCurrent LiabilitiesYoY
11.01 MUSD+38.35%
7.96 MUSD+8.24%
7.35 MUSD-51.49%
15.16 MUSD+10.09%
13.77 MUSD+36.93%
10.05 MUSD-38.87%
16.45 MUSD+243.18%
4.79 MUSD+83.67%
2.61 MUSD+98.86%
1.31 MUSD-52.13%
2.74 MUSD
Access this data via the Eulerpool API

Beyondspring Stock analysis

What does Beyondspring do? Beyondspring Inc is a globally operating biopharmaceutical company dedicated to the development of innovative cancer drugs. The company was founded in 2014 in New York City and today Beyondspring is based in New York and Shanghai. The founding of Beyondspring aimed to bring innovative cancer therapies to market that provide better treatment outcomes for patients. The company particularly focuses on a combination of proven therapeutic approaches and innovative technology, aiming to take a leading role in the oncology industry. Beyondspring focuses on the development of highly effective cancer therapies based on two platform technologies: protein engineering and immuno-oncology. The company is searching for substances that can strengthen the body's immune system and attack cancer cells. At the core of its business operations is the product Plinabulin. This is a novel cyclic peptide drug that is capable of activating the immune system and destroying cancer cells. The drug has been tested in multiple clinical trials and has shown promising results, particularly in breast cancer and lung cancer. In addition to product development, Beyondspring is also involved in the market development and commercialization of cancer drugs. The company works closely with hospitals, doctors, and other healthcare stakeholders to promote the use of Plinabulin and improve patient care. Beyondspring specializes in various types of cancer, such as lung cancer, breast cancer, and leukemia, where Plinabulin can be used. The company strives to constantly expand its product portfolio to explore additional indications. Beyondspring's business model relies on close collaboration with industry partners and the establishment of a global network. The company collaborates with leading research institutions and universities and continuously invests in the development of innovative technologies. The goal of Beyondspring is to provide cancer patients worldwide with access to innovative and highly effective treatment options. To achieve this, the company collaborates with regulatory authorities to expedite the approval of new drugs. Overall, Beyondspring is characterized by a highly dynamic and future-oriented business model. With its focus on innovative cancer therapies and the continuous expansion of its portfolio, the company has already established a strong position in the industry. In the future, Beyondspring will continue to expand its global presence and broaden its product range to provide cancer patients with the best possible treatment outcomes. Beyondspring is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beyondspring stock

Current Liabilities of Beyondspring is 11.01 M USD in 2026.

Current Liabilities of Beyondspring changed from 7.96 M USD to 11.01 M USD, representing a 38.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Beyondspring since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Beyondspring historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Beyondspring

All Key Metrics — Beyondspring